• HOME
  •  > 
  • 薬学
  •  > 
  • 雑誌
  •  >  医学と薬学　80/11　2023年11月号

医学と薬学　80/11　2023年11月号

出版社： 自然科学社
発行日： 2023-10-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 脳腫瘍に対する標準治療と薬物療法
電子書籍版： 2023-10-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,760 円(税込)

購入する

目次

  • 特集　脳腫瘍に対する標準治療と薬物療法

    脳腫瘍の分類と疫学―序文
    グリオーマに対する薬物療法
    悪性神経膠腫に対するウイルス療法
    がんゲノムプロファイリング検査とグリオーマの治療
    転移性脳腫瘍に対する薬物療法
    中枢神経系原発悪性リンパ腫に対する薬物療法
    胚細胞腫に対する薬物療法

    Diagnosis
    　RSウイルス抗原およびアデノウイルス抗原同時検出試薬
    　「ラピッドテスタ RSV−アデノsp」の臨床評価
    ルミパルス®測定システムを用いた
    　ニューロフィラメント軽鎖（脳脊髄液）測定試薬の基礎性能評価
    アポリポ蛋白A2（APOA2）アイソフォームキットの基礎性能評価

    Health Care
    　ヒト腸管オルガノイドを用いたpH調整エタノール製剤の
    　　GII. 4遺伝子型ヒトノロウイルスに対する不活性化効果の評価

    Cosmetic
    　シワ改善朝用オールインワンとシワ改善夜用オールインワンを併用した
    　　荒れ肌の即時改善効果

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 脳腫瘍に対する標準治療と薬物療法】

P.1030 掲載の参考文献
1) Fidler IJ, Yano S, Zhang RD, et al: The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 3: 53-7, 2002.
PubMed
2) 日本脳神経外科学会, 日本病理学会(編): 脳腫瘍取扱い規約第5版. 金原出版, 東京, 2023.
 
P.1035 掲載の参考文献
1) Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
PubMed
2) Gilbert MR, Wang M, Aldape KD, et al: Dosedense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31: 4085-4091, 2013.
PubMed
3) Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
PubMed
4) Herrlinger U, Tzaridis T, Mack F, et al: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393: 678-688, 2019.
PubMed
5) Brandes AA, Franceschi E, Tosoni A, et al: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26: 2192-2197, 2008.
PubMed
6) Chinot OL, Wick W, Mason W, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-722, 2014.
PubMed
7) Gilbert MR, Dignam JJ, Armstrong TS, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370: 699-708, 2014.
PubMed
8) Taphoorn MJ, Henriksson R, Bottomley A, et al: Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. J Clin Oncol 33: 2166-2175, 2015.
 
9) エーザイ株式会社: ギリアデル脳内留置用剤 7.7mg使用成績調査(全国調査)結果報告書.
 
10) Gutenberg A, Lumenta CB, Braunsdorf WE, et al: The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. J Neurooncol 113: 163-174, 2013.
PubMed
P.1042 掲載の参考文献
1) Andtbacka RH, Kaufman HL, Collichio F, et al: Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33: 2780-2788, 2015.
PubMed
2) Kaufman HL, Kohlhapp FJ, Zloza A: Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14: 642-662, 2015.
PubMed
3) Jahan N, Ghouse SM, Martuza RL, et al: In situ cancer vaccination and immunovirotherapy using oncolytic HSV. Viruses 13: 1740, 2021.
PubMed
4) Menotti L, Avitabile E: Herpes simplex virus oncolytic immunovirotherapy: The blossoming branch of multimodal therapy. Int J Mol Sci 21: 8310, 2020.
PubMed
5) Pacella I, Procaccini C, Focaccetti C, et al: Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc Natl Acad Sci USA 115: E6546-6555, 2018
PubMed
6) Sharma P, Hu-Lieskovan S, Wargo JA, et al: Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168: 707-723, 2017.
PubMed
7) Todo T, Martuza RL, Rabkin SD, et al: Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98: 6396-6401, 2001.
PubMed
8) Todo T, Ino Y, Ohtsu H, et al: A phase I/II study of triple-mutated oncolytic herpes virus G47Δ in patients with progressive glioblastoma. Nat Commun 13: 4119, 2022.
 
9) Todo T, Ito H, Ino Y, et al: Intratumoral oncolytic herpes virus G47Δ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 28: 1630-1639, 2022.
 
10) Friedman GK, Johnston JM, Bag AK, et al: Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. N Engl J Med 384: 1613-1622, 2021.
PubMed
11) Inoue H, Tani K: Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 21: 39-49, 2014.
PubMed
12) Chen DS, Mellman I: Oncology meets immunology: the cancer-immunity cycle. Immunity 39: 1-10, 2013.
PubMed
P.1047 掲載の参考文献
1) Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med 389: 589-601, 2023.
PubMed
2) Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
PubMed
3) Stupp R, Taillibert S, Kanner A, et al: Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA 318: 2306-2316, 2017.
PubMed
4) Chinot OL, Wick W, Mason W, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-722, 2014.
PubMed
5) Gilbert MR, Dignam JJ, Armstrong TS, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370: 699-708, 2014.
PubMed
6) Sunami K, Ichikawa H, Kubo T, et al: Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci 110: 1480-1490, 2019
 
P.1054 掲載の参考文献
1) Narita Y, Sato S, Kayama T: Review of the diagnosis and treatment of brain metastases. Jpn J Clin Oncol 52: 3-7, 2022.
PubMed
2) Soria JC, Ohe Y, Vansteenkiste J, et al: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378: 113-25, 2018.
PubMed
3) Wu YL, Ahn MJ, Garassino MC, et al: CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol 36: 2702-2709, 2018.
PubMed
4) Schuler M, Wu YL, Hirsh V, et al: First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol 11: 380-390, 2016.
PubMed
5) Park SJ, Kim HT, Lee DH, et al: Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77: 556-560, 2012.
PubMed
6) Iuchi T, Shingyoji M, Sakaida T, et al: Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 82: 282-287, 2013.
PubMed
7) Camidge DR, Kim HR, Ahn MJ, et al: Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. J Thorac Oncol 16: 2091-2108, 2021.
 
8) Shaw AT, Bauer TM, de Marinis F, et al: CROWN Trial Investigators. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med 383: 2018-2029. 2020
PubMed
9) Chow LQM, Barlesi F, Bertino EM, et al: ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. Clin Cancer Res 28: 2506-2516, 2022.
 
10) Gadgeel S, Peters S, Mok T, et al: Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol 29: 2214-2222, 2018.
PubMed
11) Drilon A, Siena S, Dziadziuszko R, et al: Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol 21: 261-270, 2020.
PubMed
12) Le X, Sakai H, Felip E, et al: Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res 28: 1117-1126, 2022.
PubMed
13) Subbiah V, Gainor JF, Oxnard GR, et al: Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clin Cancer Res 27: 4160-4167, 2021.
PubMed
14) Ramalingam S, Skoulidis F, Govindan R, et al: Efficacy of sotorasib in KRAS p.G12C-mutated NSCLC with stable brain metastases: a post-hoc analysis of CodeBreaK 100. J Thorac Oncol 16(Suppl 10): S1123, 2021.
 
15) Wang H, Agulnik J, Kasymjanova G, et al: The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma. Lung Cancer 132: 36-38, 2019.
PubMed
16) Mansfield AS, Aubry MC, Moser JC, et al: Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol 27: 1953-1958, 2016.
PubMed
17) Goldberg SB, Schalper KA, Gettinger SN, et al: Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol 21: 655-663, 2020.
PubMed
18) Carbon D, Cluleanu T, Cobo M, et al: OA 09.01 first-line nivolumab ipilimumab-Chemo in patients with advanced NSCLC and brain metastases: results from CheckMate 9LA J Thorac Oncol 16(Suppl 10): S862, 2021.
 
19) Besse B, Le Moulec S, Mazieres J, et al: Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. Clin Cancer Res 21: 1896-1903, 2015.
 
20) Bartsch R, Berghoff AS, Furtner J, et al: Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med 28: 1840-1847, 2022.
PubMed
21) Jerusalem G, Park YH, Yamashita T, et al: Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer Discov 12: 2754-2762, 2022
PubMed
22) Perez-Garcia JM, Vaz Batista M, Cortez P, et al: Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro Oncol 25: 157-166, 2023.
PubMed
23) Lin NU, Borges V, Anders C, et al: Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol 38: 2610-2619, 2020.
 
24) Montemurro F, Delaloge S, Barrios CH, et al: Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol 31: 1350-1358, 2020.
PubMed
25) Bachelot T, Romieu G, Campone M, et al: Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14: 64-71, 2013.
PubMed
26) Leone JP, Emblem KE, Weitz M, et al: Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res 22: 131, 2020.
PubMed
27) Dummer R, Queirolo P, Gerard Duhard P, et al: Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol: S1470-2045(23)00334-0, 2023. [Epub ahead of print]
 
28) Tawbi HA, Forsyth PA, Hodi FS, et al: Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol 22: 1692-1704, 2021.
PubMed
29) Tawbi HA, Forsyth PA, Algazi A, et al: Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379: 722-730, 2018.
 
30) Kluger HM, Chiang V, Mahajan A, et al: Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol 37: 52-60, 2019
PubMed
31) Davies MA, Saiag P, Robert C, et al: Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18: 863-873, 2017.
 
32) McArthur GA, Maio M, Arance A, et al: Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol 28: 634-641, 2017.
PubMed
33) Brastianos PK, Kim AE, Giobbie-Hurder A, et al: Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. Nat Med 29: 1728-1737, 2023.
PubMed
34) 朝尾哲彦: I. 肺がん転移性脳腫瘍の薬物治療, 癌と化学療法 49: 648-653, 2022.
 
35) 池田達彦, 前田祐佳, 佐藤綾奈, 他: II. 乳がん転移性脳腫瘍の薬物治療, 癌と化学療法 49: 654-659, 2022.
Medical*Online
36) Yang JCH, Kim SW, Kim DW, et al: Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study. J Clin Oncol 38: 538-547, 2020.
PubMed
37) Ahn MJ, Chiu CH, Cheng Y, et al: Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: The AURA leptomeningeal metastases analysis. J Thorac Oncol 15: 637-648, 2020.
PubMed
38) Alder L, Trapani D, Bradbury C, et al: Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. NPJ Breast Cancer 9: 19, 2023.
 
39) Oberkampf F, Gutierrez M, Trabelsi Grati O, et al: Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis. Neuro Oncol 25: 365-374, 2023.
PubMed
40) Kumthekar PU, Avram MJ, Lassman AB, et al: A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro Oncol 25: 557-565, 2023.
PubMed
41) Brastianos PK, Strickland MR, Lee EQ, et al. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun 12: 5954, 2021.
PubMed
42) Brastianos PK, Lee EQ, Cohen JV, et al: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med 26: 1280-1284, 2020.
PubMed
P.1062 掲載の参考文献
1) 成田善孝: 脳腫瘍の分類と疫学. 日本臨牀 79(増刊号1): 187-193, 2021.
Medical*Online
2) Brain Tumor Registry of Japan(2005-2008). Neurol med-chir 57(Supple 1): 9-102, 2017.
 
3) Chapuy B, Stewart C, Dunford AJ, et al: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24: 679-690, 2018.
PubMed
4) Schmitz R, Wright GW, Huang DW, et al: Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378: 1396-1407, 2018.
PubMed
5) Louis DN, Perry A, Wesseling P, et al: The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23: 1231-1251, 2021.
PubMed
6) 佐々木重嘉, 永根基雄: 中枢神経系原発悪性リンパ腫の治療. BRAIN and NERVE 73: 1107-1114, 2021.
 
7) DeAngelis LM, Yahalom J, Heinemann MH, et al: Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 40: 80-86, 1990.
PubMed
8) Morris PG, Correa DD, Yahalom J, et al: Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. J Clin Oncol 31: 3971-3979, 2013.
PubMed
9) Sasaki N, Kobayashi K, Saito K, et al: Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy. Jpn J Clin Oncol 50: 999-1008, 2020.
PubMed
10) Omuro AMP, Ben-Porat LS, Panageas KS, et al: Delayed Neurotoxicity in Primary Central Nervous System Lymphoma. Arch Neurol 62: 1595-1600, 2005.
PubMed
11) Correa DD, Shi W, Abrey LE, et al: Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol 14: 101-108, 2012.
PubMed
12) Doolittle ND, Korfel A, Lubow MA, et al: Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 81: 84-92, 2013.
PubMed
13) Pentsova E, Deangelis LM, Omuro A: Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neurooncol 117: 161-165, 2014.
PubMed
14) Narita Y, Nagane M, Mishima K, et al: Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol 23: 122-133, 2021.
PubMed
15) Hottinger AF, DeAngelis LM, Yahalom J, et al: Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69: 1178-1182, 2007.
PubMed
16) Ferreri AJM, Cwynarski K, Pulczynski E, et al: Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol 4: e510-523, 2017.
 
17) Rubenstein JL, Hsi ED, Johnson JL, et al: Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202(Alliance 50202). J Clin Oncol 31: 3061-3068, 2013.
PubMed
18) Nelson DF, Martz KL, Bonner H, et al: Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group(RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23: 9-17, 1992.
PubMed
19) Shibamoto Y, Ogino H, Hasegawa M, et al: Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys 62: 809-813, 2005.
PubMed
20) Schultz C, Scott C, Sherman W, et al: Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 14: 556-564, 1996.
 
21) Ott RJ, Brada M, Flower MA, et al: Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 27: 1356-1361, 1991.
PubMed
22) Pitman SW, Frei E: Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep 61: 695-701, 1977.
PubMed
23) Glass J, Gruber ML, Cher L, et al: Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81: 188-195, 1994.
PubMed
24) Hiraga S, Arita N, Ohnishi T, et al: Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 91: 221-230, 1999.
PubMed
25) Coiffier B, Lepage E, Briere J, et al: CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. N Engl J Med 346: 235-242, 2002.
PubMed
26) Ferreri AJM, Cwynarski K, Pulczynski E, et al: Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3: e217-227, 2016.
 
27) Bromberg JEC, Issa S, Bakunina K, et al: Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 20: 216-228, 2019.
PubMed
28) Shah GD, Yahalom J, Correa DD, et al: Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma. J Clin Oncol 25: 4730-4735, 2007.
PubMed
29) Motomura K, Natsume A, Fujii M, et al: Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. Leuk Lymphoma 52: 2069-2075, 2011.
PubMed
30) Chalise L, Motomura K, Ohka F, et al: Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A SingleInstitution Study. Anticancer Res 37: 5215-5223, 2017.
 
31) Batchelor T, Giri S, Ruppert AS, et al: Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance). J Clin Oncol 39(suppl 15): 7506-7506, 2021.
 
32) Houillier C, Taillandier L, Dureau S, et al: Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol 37: 823-833, 2019.
 
33) Illerhaus G, Ferreri AJM, Binder M, et al: Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation(HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma-Results of an International Randomized Phase III Trial (MATRix/IELSG43). Blood 140(Suppl 2): LBA-3, 2022.
 
34) Schorb E, Finke J, Ihorst G, et al: Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. BMC Cancer 19: 287, 2019.
 
35) Kondo E, Ikeda T, Izutsu K, et al: High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry. Biol Blood Marrow Transplant 25: 899-905, 2019.
 
36) Hoang-Xuan K, Deckert M, Ferreri AJM, et al: European Association of Neuro-Oncology(EANO) guidelines for treatment of primary central nervous system lymphoma(PCNSL). Neuro Oncol 25: 37-53, 2023.
PubMed
37) Lurain K, Uldrick TS, Ramaswami R, et al: Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. Blood 136: 2229-2232, 2020.
PubMed
38) Kaji FA, Martinez-Calle N, Sovani V, et al: Rare central nervous system lymphomas. Br J Haematol 197: 662-678, 2022.
PubMed
39) Fonkem E, Lok E, Robison D, et al: The natural history of intravascular lymphomatosis. Cancer Med 3: 1010-1024, 2014.
PubMed
40) Liu Z, Zhang Y, Zhu Y, et al: Prognosis of Intravascular Large B Cell Lymphoma(IVLBCL): Analysis of 182 Patients from Global Case Series. Cancer Manag Res 12: 10531-10540, 2020.
 
41) Nizamutdinov D, Patel NP, Huang JH, et al: Intravascular Lymphoma in the CNS: Options for Treatment. Curr Treat Options Neurol 19: 35, 2017.
 
42) Shimada K, Yamaguchi M, Atsuta Y, et al: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. The Lancet Oncology 21: 593-602, 2020.
 
43) Kebir S, Kuchelmeister K, Niehusmann P, et al: Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy. Exp Hematol Oncol 1: 37, 2012.
PubMed
44) Wang J, Alhaj Moustafa M, Kuhlman JJ, et al: Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy. Blood Lymphat Cancer 12: 47-54, 2022.
 
45) Momota H, Narita Y, Miyakita Y, et al: Intravascular lymphoma of the central nervous system presenting as multiple cerebral infarctions. Nagoya J Med Sci 74: 353-358, 2012.
PubMed
46) Chihara D, Fowler NH, Oki Y, et al: Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget 9: 28897-28902, 2018.
PubMed
47) Aqil B, Rouah E, Verstovsek G: Primary CNS Marginal Zone Lymphoma: A Case Report and Review of the Literature. J Pathol 03(02): 55-59, 2013.
 
48) Laghaei Farimani P, Karthikeyan V, Fatehi M, et al: Intraparenchymal Mucosa-Associated Lymphoid Tissue Lymphoma: A Case Report. Cureus 14: e28301, 2022.
PubMed
49) Ayanambakkam A, Ibrahimi S, Bilal K, et al: Extranodal Marginal Zone Lymphoma of the Central Nervous System. Clin Lymphoma Myeloma Leuk 18: 34-37.e8, 2018.
 
50) Desjardins C, Larrieu-Ciron D, Choquet S, et al: Chemotherapy is an efficient treatment in primary CNS MALT lymphoma. J Neurooncol 159: 151-161, 2022.
PubMed
51) Hayabuchi N, Shibamoto Y, Onizuka Y: Primary central nervous system lymphoma in japan: a nationwide survey. Int J Radiat Oncol Biol Phys 44: 265-272, 1999.
PubMed
52) Shenkier TN, Blay JY, O'Neill BP, et al: Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group. J Clin Oncol 23: 2233-2239, 2005.
 
53) Hirano Y, Miyawaki S, Tanaka S, et al: Clinical Features and Prognostic Factors for Primary Anaplastic Large Cell Lymphoma of the Central Nervous System: A Systematic Review. Cancers 13: 4358, 2021.
PubMed
P.1069 掲載の参考文献
1) Louis DN, Perry A, Wesseling P, et al: The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23: 1231-1251, 2021.
PubMed
2) Takami H, Graffeo CS, Perry A, et al: Impact of tumor markers on diagnosis, treatment and prognosis in CNS germ cell tumors: correlations with clinical practice and histopathology. Brain Tumor Pathol 40: 124-132, 2023.
PubMed
3) Nakamura H, Takami H, Yanagisawa T, et al: The Japan society for neuro-oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors. Neuro Oncol 24: 503-515, 2022.
 
4) Takami H, Fukuoka K, Fukushima S, et al: Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium. Neuro Oncol 21: 1565-1577, 2019.
PubMed
5) Matsutani M, Sano K, Takakura K, et al: Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg 86: 446-455, 1997.
 
6) Takami H, Suzuki T, Takabatake K, et al: PEDT-10 PHASE II TRIAL OF PATHOLOGY-BASED THREE-GROUP TREATMENT STRATIFICATION FOR PATIENTS WITH CNS GERM CELL TUMORS: A LONG-TERM FOLLOW-UP STUDY. Neuro Oncol Advances 4(Suppl 3): iii11, 2022.
 
7) Bartels U, Onar-Thomas A, Patel SK, et al: Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study. Neuro Oncol 24: 974-983, 2022.
 
8) Fangusaro J, Wu S, MacDonald S, et al: Phase II trial of response-based radiation therapy for patients with localized CNS nongerminomatous germ cell tumors: a Children's Oncology Group Study. J Clin Oncol 37: 3283-3290, 2019.
 
9) Ichimura K, Fukushima S, Totoki Y, et al: Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy. Acta Neuropathol 131: 889-901, 2016.
PubMed
10) Wang L, Yamaguchi S, Burstein MD, et al: Novel somatic and germline mutations in intracranial germ cell tumours. Nature 511: 241-245, 2014.
PubMed
11) Liu B, Arakawa Y, Yokogawa R, et al: PD-1/PD-1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes. PLoS One 13: e0194594, 2018.
 
12) Takami H, Fukushima S, Aoki K, et al: Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance. Neuropathol Appl Neurobiol 46: 111-124, 2020.
PubMed
13) Wildeman ME, Shepard MJ, Oldfield EH, et al: Central Nervous System Germinomas Express Programmed Death Ligand 1. J Neuropathol. Exp Neurol 77: 312-316, 2018.
PubMed
14) Takami H, Elzawahry A, Mamatjan Y, et al: Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts. Neuro Oncol 24: 1246-1258, 2022.
PubMed
15) Schepisi G, Gianni C, Cursano MC, et al: Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR) -T cell therapy: Potential treatment options against Testicular Germ Cell Tumors. Front Immunol 14: 1118610, 2023.
PubMed
16) Acharya S, DeWees T, Shinohara ET, et al: Long-term outcomes and late effects for childhood and young adulthood intracranial germinomas. Neuro Oncol 17: 741-746, 2015.
 

【Diagnosis】

P.1082 掲載の参考文献
1) 堤 裕幸: RSウイルスウイルス. ウイルスウイルス 55: 77-84, 2005
 
2) 山崎雅彦, 三田村敬子: RSウイルス, ヒトメタニューモウイルス. 小児科診療 67: 1443-1448, 2022.
 
3) 日本小児科学会: 重症RSウイルス感染症の実態調査. 日本小児科学会雑誌 124: 927-936, 2020.
 
4) 堀越裕歩: 感染症の迅速検査. 小児科診療 81: 1647-1652, 2018.
Medical*Online
5) 日本小児感染症学会: 日常診療に役立つ小児感染症マニュアル 2017. pp.327-339, 東京医学社, 東京, 2017.
 
6) 齋藤昭彦: 小児の RSウイルス感染症・溶連菌咽頭炎. 感染と抗菌薬 23: 249-253, 2020.
Medical*Online
7) 上紙真未: コロナウイルス感染症 2019 流行中のRSウイルス感染症流行疫学. 小児科臨床 75: 591-596, 2020.
 
8) 脇口 宏: アデノウイルス感染症. 臨牀と研究 79: 2095-2098, 2003.
 
9) 鈴木 宏: アデノウイルス. 化学療法の領域 15: 1543-1547, 1999.
 
10) 藤本嗣人: アデノウイルス感染症に対する迅速診断法の進歩. 臨床とウイルス 33: 121-125, 2005.
Medical*Online
11) IASR(感染症情報センター): 成人における RSウイルスの集団感染. IASR 39: 211-212, 2018.
 
12) 若林義賢, 久朗津尚美, 丸茂一義: 当院で経験した単一施設内でのアデノウイルスの集団感染による肺炎の事例. 日呼吸誌 3: 580-584, 2014.
 
13) 田村大輔, 山崎雅彦, 市川正孝, 他: RSウイルス抗原およびアデノウイルス抗原同時検出試薬「ラピッドテスタ RSV-アデノ・NEXT」の臨床評価. 医学と薬学 80: 499-512, 2023.
Medical*Online
P.1088 掲載の参考文献
1) Olsson B, Portelius E, Cullen NC, et al: Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurol 76(3): 318-325, 2019.
PubMed
2) Yamasaki H, Itakura C, Mizutani M: Hereditary hypotrophic axonopathy with neurofilament deficiency in a mutant strain of the Japanese quail. Acta Neuropathol 82(6): 427-434, 1991.
 
3) Yuan A, Nixon RA: Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies. Front Neurosci 15: 689938, 2021.
PubMed
4) Gaetani L, Blennow K, Calabresi P, et al: Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8): 870-881, 2019.
 
5) Miller TM, Cudkowicz ME, Genge A, et al: Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 387(12): 1099-1110, 2022.
 
6) Jack CR, Jr., Bennett DA, Blennow K, et al: NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement 14(4): 535-562, 2018.
 
7) Zetterberg H, Bendlin BB: Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry 26(1): 296-308, 2021.
PubMed
8) Kasuga K, Kikuchi M, Tsukie T, et al: Different AT (N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluid. BMJ Neurol Open 4(2): e000321, 2022.
 
9) Kasuga K, Tsukie T, Kikuchi M, et al: The clinical application of optimized AT(N) classification in Alzheimer's clinical syndrome (ACS) and non-ACS conditions. Neurobiol Aging 127: 23-32, 2023.
PubMed
10) Mattsson N, Andreasson U, Persson S, et al: CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 9(3): 251-261, 2013.
PubMed
11) Sato C, Barthelemy NR, Mawuenyega KG, et al: Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 97(6): 1284-1298e1287, 2018.
PubMed
12) Ashton NJ, Janelidze S, Al Khleifat A, et al: A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun 12(1): 3400, 2021.
PubMed
13) Bridel C, van Wieringen WN, Zetterberg H, et al: Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol 76(9): 1035-1048, 2019.
 
14) Zetterberg H, Skillback T, Mattsson N, et al: Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol 73(1): 60-67, 2016.
PubMed
15) Kern S, Syrjanen JA, Blennow K, et al: Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA Neurol 76(2): 187-193, 2019.
PubMed
16) Disanto G, Barro C, Benkert P, et al: Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81(6): 857-870, 2017.
 
17) Pontecorvo MJ, Lu M, Burnham SC, et al: Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol 79(12): 1250-1259, 2022.
PubMed
18) Nojima H, Ito S, Kushida A, et al: Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(R) system. Ann Clin Transl Neurol 9(12): 1898-1909, 2022.
 
P.1096 掲載の参考文献
1) Honda K, Okusaka T, Felix K, et al: Altered plasma apolipoprotein modifications in patients with pancreatic cancer: Protein characterization and multi-institutional validation. PLoS One 7: e46908, 2012.
PubMed
2) Honda K, Kobayashi M, Okusaka T, et al: Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Sci Rep 5: 15921, 2015.
PubMed
3) Kashiro A, Kobayashi M, Oh T, et al: Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. 55th European Pancreatic Club Meeting, Alpbach, Tyrol, Austria, June 28th -July 1st 2023.
 

【Health Care】

P.1103 掲載の参考文献
1) Sarah M Bartsch, Benjamin A Lopman, Sachiko Ozawa, et al: Global economic burden of norovirus gastroenteritis. PLoS One 11(4): e0151219, 2016.
 
2) Benjamin A Lopman, Duncan Steele, Carl D Kirkwood, et al: The vast and varied global burden of norovirus: prospects for prevention and control. PLoS Medicine 13(4): e1001999, 2016.
 
3) Albert Z Kapikian, Richard G Wyatt, Raphael Dolin, et al: Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. Journal of virology 10(5): 1075-1081, 1972.
 
4) Kampf Gunter: Efficacy of ethanol against viruses in hand disinfection. Journal of Hospital Infection 98(4): 331-338, 2018.
 
5) A Kramer, A S Galabov, S A Sattar, et al: Virucidal activity of a new hand disinfectant with reduced ethanol content: comparison with other alcohol-based formulations. Journal of Hospital Infection 62(1): 98-106, 2006.
 
6) J Steinmann, D Paulmann, B Becker, et al: Comparison of virucidal activity of alcohol-based hand sanitizers versus antimicrobial hand soaps in vitro and in vivo. Journal of Hospital Infection 82(4): 277-280, 2012.
 
7) David R Macinga macinga, Syed A Sattar, Lee-Ann Jaykus, et al: Improved inactivation of nonenveloped enteric viruses and their surrogates by a novel alcohol-based hand sanitizer. Applied and environmental microbiology 74(16): 5047-5052, 2008.
PubMed
8) Yuko Shimizu-Onda, Tempei Akasaka, Fumihiro Yagyu, et al: The virucidal effect against murine norovirus and feline calicivirus as surrogates for human norovirus by ethanol-based sanitizers. Journal of Infection and Chemotherapy 19(4): 779-781, 2013.
 
9) Khalil Ettayebi, Sue E Crawford, Kosuke Murakami, et al: Replication of human noroviruses in stem cell-derived human enteroids. Science 353(6306): 1387-1393, 2016.
PubMed
10) Veronica Costantini, Esther K Morantz, Hannah Browne, et al: Human norovirus replication in human intestinal enteroids as model to evaluate virus inactivation. Emerging infectious diseases 24(8): 1453-1464, 2018.
PubMed
11) B H Keswick, T K Satterwhite, P C Johnson, et al: Inactivation of Norwalk virus in drinking water by chlorine. Applied and Environmental Microbiology 50(2): 261-264, 1985.
 
12) 戸高玲子, 藤本 陽, 芳賀 慧, 他: ヒト腸管オルガノイドを用いた市販アルコール系製品のヒトノロウイルスの不活性化効果の評価. 感染制御と予防衛生 5(2): 98-106, 2021.
Medical*Online
13) Shintaro Sato, Kota Hisaie, Shiho Kurokawa, et al: Human norovirus propagation in human induced pluripotent stem cell-derived intestinal epithelial cells. Cellular and Molecular Gastroenterology and Hepatology 7(3): 686-688, 2019.
PubMed
14) Shintaro Sato, Naomi Matsumoto, Kota Hisaie, et al: Alcohol abrogates human norovirus infectivity in a pH-dependent manner. Scientific reports 10(1): 1-10, 2020.
 
15) Tsutomu Kageyama, Shigeyuki Kojima, Michiyo Shinohara, et al: Broadly reactive and highly sensitive assay for Norwalk-like viruses based on real-time quantitative reverse transcription-PCR. Journal of clinical microbiology 41(4): 1548-1557, 2003.
PubMed
16) M E Hardy, L J White, J M Ball, et al: Specific proteolytic cleavage of recombinant Norwalk virus capsid protein. Journal of Virology 69(3): 1693-1698, 1995.
 

【Cosmetic】

P.1108 掲載の参考文献
1) Tanioka M, Yamada M, Doi Y, et al: Molecular Clocks in Mouse Skin J Invest Dermatol 129(5): 1225-1231, 2009.
 
2) Yosipovitch G, Xiong L, Haus E., Sackett-Lundeen L, et al: Time-Dependent Variations of the Skin Barrier Function in Humans: Transepidermal Water Loss, Stratum Corneum Hydration, Skin Surface pH, and Skin Temperature. J Invest Dermatol 110: 20-23, 1998.
 
3) Le Fur I, Reinberg A, Lopez S, et al: Analysis of Circadian and Ultradian Rhythms of Skin Surface Properties of Face and Forearm of Healthy Women. J Invest Dermatol 117: 718-724, 2001.
PubMed
4) Imokawa G, Hattori M: A Possible Function of Structural Lipids in the Water-Holding Properties of the Stratum Corneum. J Invest Dermatol 84: 282-284, 1985.
 
5) 石川 正, 大なぎ 進: 口唇形状の検討 -面積測定による評価-. 昭医会 56(5): 107-113, 2018.
 
6) 枝 伸彦: 皮膚および粘膜の感染予防機能に対する運動の影響. 早稲田大学博士論文, 甲第3885号, 2013.
 
7) 高橋元次: 肌の状態を調べ, 効能を評価するために非侵襲的皮膚計測技術. J Soc Cosmet Chem jpn 51(2): 105-116, 2017.
 
8) 岩井秀隆, 亀井菜々子, 吉田健久: 朝用オールインワンと夜用オールインワンを使い分けて使用した場合の荒れ肌改善効果. 医学と薬学 80(6): 635-642, 2023.
Medical*Online
9) 白井喜代子, 山本尚武, 奥田博之: 各種皮膚水分センサと女性の前腕表皮角質層の水分変動. 生体医工学 40(supplement 2): 152, 2002.
 

書評

最近チェックした商品履歴

Loading...